Catalyst Pharmaceuticals
CPRX
Performance
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing therapies for rare diseases. The company highlights its work in improving lives through novel and efficacious treatments, with emphasis on conditions such as Lambert-Eaton myasthenic syndrome, epilepsy, and Duchenne muscular dystrophy, and operates in the United States. It emphasizes scientific research, patient-focused programs, and responsible corporate citizenship, including compassionate use programs and ESG reporting.
Recent News
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
Pharma and Biotech M&As 2026 Deal Watcher
InsideArbitrage Event Driven Monitor – June 9, 2026
InsideArbitrage Event Driven Monitor – May 29, 2026
InsideArbitrage Event Driven Monitor – May 8, 2026
GameStop’s Unusual and Complex Bid for eBay – The Special Situations Report Episode 66
CVC and GBL Unveil €10.7 Bn Take‑Private Offer for Recordati
Italy’s Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement
Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion
GSK to Acquire Nuvalent in Largest Deal in Over a Decade – Merger Arbitrage Mondays